Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

NCT06068985 is registered in ClinicalTrials.gov with Latin American Cooperative Oncology Group as lead sponsor.

NCT NCT06068985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06068985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade
Lead sponsor
Latin American Cooperative Oncology Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 5, 2024
Completion date
November 30, 2032
Enrollment
63 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-positive breast cancer